Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Grant
Adjust height of sidebar
KMap
Grant
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Sponsored by Caribou Biosciences Inc.
Active
$464.7K Funding
1 People
External
Related Topics
cell therapy,
cancer treatment,
crispr,
lymphoma,
clinical trial
People
Michele Chu-Pilli
(CD)
Cancer Center Division
﹒Research Program Administration Officer III
